louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05043389: Impact of Myofuntional Therapy Program on Increasing Tongue Strength and Improving Sleep Apnea
Official title: Impact of Myofuntional Therapy Program on Increasing Tongue Strength and Improving Sleep Apnea: a Randomized Controlled Trail
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obstructive Sleep Apnea
Keywords: myofunctional therapy
IOPI
Obstructive sleep apnea (OSA)
Lead sponsor: Department of Medical Services Ministry of Public Health of Thailand
Sponsor class: OTHER_GOV
First posted: 2021-09-14
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This Research studies for compare muscle strength among OSA patients who treat with myofunctional therapy program in Rajavithi hospital


Eligibility criteria: Inclusion Criteria:

* Patients who diagnose with Obstructive sleep apnea 18-65 years

Exclusion Criteria:

* BMI\>=35kg/m2
* alcoholic and smoke
* use sleeping pill
* craniofacial syndrome
* hypertrophic tonsils grade 3+, 4+
* severe comorbidity
* Use CAP

Primary outcomes:
measure: Compare muscle strength
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Rajavithi Hospital
Study officials:
affiliation: Department of Medical Services Ministry of Public Health of Thailand
name: Sasion Phaibunphunphiphat, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05767489: Study of Brain Anatomo-functional Substrates Related to the Use of Human Tool by Means of Simultaneous Acquisition of Magnetic Resonance Imaging and Electroencephalogram
Official title: Study of Brain Anatomo-functional Substrates Related to the Use of Human Tool by Means of Simultaneous Acquisition of Magnetic Resonance Imaging and Electroencephalogram
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Patients With Frontal and Parietal Lobe Dysfunction
Lead sponsor: IRCCS SYNLAB SDN
Sponsor class: OTHER
First posted: 2023-03-14
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects with brain dysfunction, particularly affecting the lobe frontal, temporal and parietal

Brief summary: This is an observational study, conducted on subjects with neurological disorders primarily involving the frontal and parietal lobes of the brain. Throughout the indicated period, the study will aim to enroll 100 subjects divided into 30 units per year. Specifically, the study will be carried out on patients with fronto-parietal dysfunction for whom a prescribed a clinical investigation of electroencephalogram and MRI


Eligibility criteria: Inclusion Criteria:

* subjects of either sex with fronto-parietal dysfunction, who are able to able to provide voluntary consent, who have been asked for clinical purposes for an EEG and an MRI

Exclusion Criteria:

* pregnant or presumed pregnant subjects and subjects with claustrophobia or with contraindications to the examination.

Primary outcomes:
measure: Combination of EEG and functional MR (fMRI)
timeFrame: 1-36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Naples
country: Italy
facility: IRCCS Synlab SDN
Study officials:
References:
Clinical trial NCT01925989: A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
Official title: Evaluation of the Effects of Insulin Peglispro (LY2605541) on Respiratory Quotient During Sleep and Response to Hyperinsulinemia Compared With That of Insulin Glargine in Patients With Type 1 Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Type 1 Diabetes Mellitus
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2013-08-20
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: This is a two-period study of participants with type 1 diabetes mellitus (T1DM). In each period, participants will receive once daily injections of stable dose LY2605541 or insulin glargine for 28 to 35 days followed by procedures to look at how the body uses or stores fats and sugars. Participants will continue to use meal time insulin throughout the study. Healthy participants will also enroll in the study. They will not receive any study medication.


Eligibility criteria: Inclusion Criteria:

Type 1 Diabetics:

- T1DM for more than 1 year with Hemoglobin A1c (HbA1c) of less than 9.5%

All Participants:

* Otherwise fit and healthy
* Non smoker

Exclusion Criteria:

Type 1 Diabetics:

* Taking medication or supplements other than insulin to control diabetes
* Suffered a hypoglycemic event in the last 12 months that required hospitalization or have poor awareness of hypoglycemia

All Participants:

- Taking fibrates, thyroid replacement therapy, testosterone, beta blockers or systemic corticosteroids

Primary outcomes:
measure: Sleep Respiratory Quotient (RQ) in Type 1 Diabetes Mellitus (T1DM)
timeFrame: Day 30 post dose, overnight period (0000 to 0600 hours)
Secondary outcomes:
measure: Lipid Oxidation in T1DM and Healthy Participants
timeFrame: Day 30 post dose, overnight period (0000 to 0600 hours)
measure: Basal Metabolic Rate (BMR) for T1DM
timeFrame: Day 30 post dose, overnight period (0000 to 0600 hours)
measure: Sleep Respiratory Quotient (RQ) of Untreated Healthy Participants
timeFrame: Day 5, overnight period (0000 to 0600 hours)
measure: Total Number of Minutes of Lipid Oxidation (RQ Below 7.6) in T1DM and Healthy Participants
timeFrame: Day 5, every minute through 23 hour period
measure: Change in RQ, Pre-breakfast to Post-breakfast Meal, in T1DM
timeFrame: Day 30 0830 to 0854 hours, Day 30 1000 to 1054 hours
Other outcomes:
Locations:
city: Orlando
country: United States
facility: Translational Research Institute for Metabolism and Diabetes
state: Florida
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT04217889: Cystic Fibrosis Adherence Study
Official title: Study of the Adherence to Chest Physiotherapy in Patients With Cystic Fibrosis (CF) at the Adult CF Center in Lyon
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cystic Fibrosis
Keywords: Cystic Fibrosis
Adherence to chest physiotherapy
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2020-01-06
Enrollment: 197
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Cohort of adult patients with cystic fibrosis and follow-up at the Lyon Reference Center.

Brief summary: This study aims to assess the role of some factors which can influence the chest physiotherapy adherence in adult with cystic fibrosis.

At first, we are going to try to consider the adherence of chest physiotherapy. Then, after dividing the patients into two groups - adherent or not adherent - we will attempt to identify the factors which can influence this adherence.

It consists in a short questionnaire that the patient will fill during usual visits.

The hypothesis is that the following factors can play a role in adherence of chest physiotherapy:

* Age
* Age of diagnostic
* Sex
* Fev1
* Number of antibiotic course
* Anxiety/depression
* Work time
* Socio-professional category
* Individual situation
* Physiotherapy with liberal physiotherapist and transport time
* Sport practice
* Family support
* Feeling of work time burden
* Feeling of physiotherapy efficiency
* Feeling of physiotherapy burden


Eligibility criteria: Inclusion Criteria:

* respiratory symptoms
* subnormal respiratory function (FEV1 \< 80%)
* without lung transplant

Exclusion Criteria:

* lung transplantation approach

Primary outcomes:
measure: Quantity of chest physiotherapy
timeFrame: 8 months
Secondary outcomes:
Other outcomes:
Locations:
city: Pierre-Bénite
country: France
facility: Centre de Référence de la Mucoviscidose Lyon à l'hôpital Lyon Sud
Study officials:
References:
Clinical trial NCT00511589: Chagas Disease Diagnostic - Inconclusive Serology
Official title: PCR in Blood Cultures of Individuals With Positive and Inconclusive Serology for Chagas' Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Parasitemia
Protozoan Infections
Lead sponsor: UPECLIN HC FM Botucatu Unesp
Sponsor class: OTHER
First posted: 2007-08-06
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Intervention model: PARALLEL

Brief summary: T. cruzi infection affects approximately five million people in Brazil. The diagnosis of the chronic phase of infection is performed by indirect serological methods which, nevertheless, leave inconclusive results. One of the direct methods used for T. cruzi identification, blood culture in LIT (liver infusion tryptose) medium, presents low sensitivity in that phase of the disease. A negative result does not eliminate the possibility of infection, but a positive test has high absolute diagnostic value, which enables the indication of antiparasitic treatment. Molecular diagnosis (PCR) in this phase is promising and can be used as a confirmatory test, particularly when individuals present inconclusive results in conventional serological tests, such as ELISA, HAI and IFI. This study aimed at improving blood culture sensitivity in LIT medium by performing PCR in individuals with positive and inconclusive serology for chagasic infection.


Eligibility criteria: Inclusion Criteria:

* individuals with positive or inconclusive results in conventional serological tests: ELISA, HAI and IFI for Chagas disease

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Botucatu
country: Brazil
facility: Univerdidade Estadual Paulista
state: São Paulo
Study officials:
affiliation: UPECLIN HC FM Botucatu Unesp
name: Mariele Cristina M Picka, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05437744: Immediately Placed Implant Sealed With Platelets Rich Fibrin Versus Cyanoacrylate Glue
Official title: Assessment of Soft Tissue Healing Over Immediately Placed Implant Sealed With Platelets Rich Fibrin (Prf) Versus Cyanoacrylate Glue (a Randomized Controlled Clinical Trial)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Tooth Socket
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2022-06-29
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The health of peri-implant soft tissues is one of the most important aspects necessary for the long-term survival of dental implants. The importance of the peri-implant mucosal region lies in the need to establish a tight seal that isolates the implant and the bone from the oral environment. Study objective is to clinically compare the soft tissue healing, height, and thickness over immediate implants placed in type I sockets sealed by PRF to those sealed by a Cyanoacrylate glue.

Detailed description: the study will be conducted on 16 extraction sockets in humans. Sockets will be randomly divided into two groups: Group I (test) will comprise 8 sockets sealed by PRF after immediate implant placement. Group II: (test) will comprise 8 sockets sealed by cyanoacrylate glue after immediate implant placement

Eligibility criteria: Inclusion Criteria:

* Any non-restorable hopeless tooth; a badly decayed tooth that cannot be restored, a Tooth with failed endodontic treatment, and tooth with longitudinal fracture.
* Post-extraction sockets type 1 with all bony walls intact; Type I extraction sockets according to Elian classification in 2007 have an intact labial plate of the bone and no soft tissue recession. Therefore, it does not require a mucoperiosteal flap elevation, only bone graft particles are packed into the socket after atraumatic extraction and socket debridement, then sealed with barrier membranes or soft tissue graft
* A good standard of oral hygiene.
* No signs of active periodontal disease in the selected tooth.

Exclusion Criteria:

* The presence of any systemic disease that could complicate bone or soft tissue healing after immediate implant placement.
* The presence of Acute periapical infection.
* The presence of any local factor that may interfere with extraction as tooth ankyloses. (
* Subjects who had undergone therapeutical radiation. (38)
* Patients who had been subjected to or who were under bisphosphonate therapy

Primary outcomes:
measure: Change in soft tissue healing
timeFrame: at 2nd week and 4th week
measure: Change in Mid crestal soft tissue thickness
timeFrame: at baseline and after 4 weeks
measure: change in Mid-buccal soft tissue height
timeFrame: at baseline and after 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Alexandria Faculty of Dentistry
Study officials:
References:
Clinical trial NCT02849340: Combination of Cryosurgey and NK Immunotherapy for Recurrent Cervical Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Recurrent Cervical Cancer
Keywords: Cervical Cancer
cryosurgery
NK immunotherapy
Lead sponsor: Fuda Cancer Hospital, Guangzhou
Sponsor class: OTHER
Collaborators: name: Shenzhen Hank Bioengineering Institute
First posted: 2016-07-29
Enrollment: 30
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to recurrent cervical cancer.

Detailed description: By enrolling patients with recurrent cervical cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using cryosurgery and natural killer (NK) cells.

The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

Eligibility criteria: Inclusion Criteria:

* All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence
* Body tumor 1-6, the maximum tumor length \< 5 cm
* KPS ≥ 70, lifespan \> 6 months
* Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L

Exclusion Criteria:

* Patients with cardiac pacemaker
* Patients with brain metastasis
* Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction

Primary outcomes:
measure: Relief degree of tumors
timeFrame: 3 months
Secondary outcomes:
measure: Progress free survival（PFS）
timeFrame: 1 year
measure: Overall survival（OS）
timeFrame: 3 years
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Fuda cancer institute of Fuda cancer hospital
state: Guangdong
Study officials:
affiliation: Fuda Cancer Hospital, Guangzhou
name: Jibing Chen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00363844: Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus
Official title: MK-0431/ONO-5435 Phase III Clinical Study - Long-term Treatment Study for Patients With Type 2 Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Type 2 Diabetes Mellitus
Keywords: MK-0431
ONO-5435
Type 2 diabetes mellitus
Lead sponsor: Ono Pharmaceutical Co. Ltd
Sponsor class: INDUSTRY
First posted: 2006-08-15
Enrollment: 209
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Determine the safety and efficacy of MK-0431/ONO-5435 in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy


Eligibility criteria: Inclusion Criteria:

* Patients with type 2 diabetes mellitus on diet and exercise therapy

Exclusion Criteria:

* Patients with type 1 diabetes mellitus

Primary outcomes:
measure: safety
timeFrame: 52 weeks
measure: tolerability
timeFrame: 52 weeks
Secondary outcomes:
measure: HbA1c
timeFrame: 52 weeks
measure: Plasma glucose
timeFrame: 52 weeks
Other outcomes:
Locations:
city: Chubu
country: Japan
facility: Chubu Region
city: Chugoku
country: Japan
facility: Chugoku Region
city: Hokkaido
country: Japan
facility: Hokkaido Region
city: Kanto
country: Japan
facility: Kanto Region
city: Kinki
country: Japan
facility: Kinki Region
city: Kyushu
country: Japan
facility: Kyushu Region
city: Shikoku
country: Japan
facility: Shikoku Region
city: Tohoku
country: Japan
facility: Tohoku Region
Study officials:
affiliation: Ono Pharmaceutical Co. Ltd
name: Mikio Nishii
role: STUDY_DIRECTOR
References:
Clinical trial NCT06480344: Analysis of Risk Factors for Surgical Site Infections in Patients With Acute Abdomen at Hospital of State University of Haiti
Official title: Risk Factors Associated With the Occurrence of Surgical Site Infections (SSI) in Patients Operated for Acute Abdomen at Hôpital de l'Université d'Etat d'Haiti (HUEH) From January 2018 to December 2020
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Surgical Site Infection
Post-Op Infection
Keywords: Surgical site infection
NNIS index
Post-operative infection
Lead sponsor: University of Haiti
Sponsor class: OTHER
Collaborators: name: Christopher Williams Valsaint
name: Axler Jean-Paul
First posted: 2024-06-28
Enrollment: 87
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The participants selected in our study include those who have developed an infection at the operating site (case) as well as those who have not developed it (controls) following acute abdominal surgery diagnosed in post-op room at the surgery department of The State University of Haiti, from January 2018 to December 2022.

Brief summary: The purpose of this study is to identify the risk factors associated with surgical site infection.

Detailed description: 87 patients medical records from January 2018 to December 2020 will be analyzed to detect the risk factors linked to the occurence of surgical site infection. Then the strength of their association with surgical site infection will be determined via multivariate analysis.

Eligibility criteria: Inclusion Criteria:

* Female or male patients over 12 years of age.
* Admitted to the Surgery Department for acute surgical abdomen and having undergone surgery

Exclusion Criteria:

* Patients who have undergone abdominal surgery for urological or gynecological pathologies
* Files with missing information on preoperative, operative and post-operative arrangements

Primary outcomes:
measure: Occurence of surgical site infection
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Port-au-Prince
country: Haiti
facility: Hopital de l'Université d'Etat d'Haiti
state: Ouest
Study officials:
References:
Clinical trial NCT03344744: miRNA Profile in Aneurysmal Subarachnoid Haemorrhage
Official title: Circulating and CSF miRNA Profile in Patients With Acute Aneurysmal Subarachnoid Haemorrhage
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Subarachnoid Hemorrhage
Keywords: Subarachnoid Haemorrhage
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2017-11-17
Enrollment: 100
Sex: ALL
Minimum age (years): 21
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: * Acute aneurysmal subarachnoid hemorrhage patients with and without delayed cerebral infarction
* Healthy volunteers

Brief summary: The investigators aim to investigate and understand the circulating miRNA profiles after acute aneurysmal subarachnoid haemorrhage and underlying pathological significance.

Detailed description: 1. The investigators aim to investigate the miRNA classifier for delayed cerebral infarction after aneurysmal subarachnoid haemorrhage;
2. The investigators aim to investigate the corresponding circulating and CSF miRNA profiles.

Eligibility criteria: Inclusion Criteria:

Aneurysmal subarachnoid hemorrhage patients within the first 72 hours or Healthy volunteers

Exclusion Criteria:

Previous neurological diseases such as stroke or dementia

Primary outcomes:
measure: Circulating micro RNA concentrations
timeFrame: Day 3
Secondary outcomes:
measure: Circulating micro RNA change
timeFrame: Days 1,2,3,7
measure: Cerebrospinal fluid micro RNA concentrations
timeFrame: Day 1,2,3,7
measure: Cerebrospinal fluid micro RNA change
timeFrame: Days 1,2,3,7
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: Department of Surgery, The Chinese University of Hong Kong
Study officials:
affiliation: Chinese University of Hong Kong
name: George KC Wong
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lu G, Wong MS, Xiong MZQ, Leung CK, Su XW, Zhou JY, Poon WS, Zheng VZY, Chan WY, Wong GKC. Circulating MicroRNAs in Delayed Cerebral Infarction After Aneurysmal Subarachnoid Hemorrhage. J Am Heart Assoc. 2017 Apr 25;6(4):e005363. doi: 10.1161/JAHA.116.005363.
citation: Su XW, Chan AH, Lu G, Lin M, Sze J, Zhou JY, Poon WS, Liu Q, Zheng VZ, Wong GK. Circulating microRNA 132-3p and 324-3p Profiles in Patients after Acute Aneurysmal Subarachnoid Hemorrhage. PLoS One. 2015 Dec 16;10(12):e0144724. doi: 10.1371/journal.pone.0144724. eCollection 2015.
citation: Wong GK, Lam S, Ngai K, Wong A, Mok V, Poon WS; Cognitive Dysfunction after Aneurysmal Subarachnoid Haemorrhage Investigators. Evaluation of cognitive impairment by the Montreal cognitive assessment in patients with aneurysmal subarachnoid haemorrhage: prevalence, risk factors and correlations with 3 month outcomes. J Neurol Neurosurg Psychiatry. 2012 Nov;83(11):1112-7. doi: 10.1136/jnnp-2012-302217. Epub 2012 Jul 31.